Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB

International Immunopharmacology

Volumn 9, Issue 13-14, 2009, Pages 1530-1539

  Park, Jae Yeo ^a,b   Jang, Min Ja ^a   Chung, Yoon Hee ^a   Kim, Kyung Yong ^a   Kim, Sung Su ^a   Lee, Won Bok ^a   You, Seungkwon ^b   Choi, Youn Seok ^c   Hur, Dae Young ^d   Kim, Daejin ^a  

^a Chung Ang University   (South Korea)

^b Korea University   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Inje University   (South Korea)

Author keywords

4 1BB; CD4; CD40 ligand; Doxorubicin

Indexed keywords

CD137 LIGAND; CD40 LIGAND; DNA VACCINE; DOXORUBICIN; GAMMA INTERFERON;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD; BIOLISTICS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL SURVIVAL; COCULTURE TECHNIQUES; DENDRITIC CELLS; DOXORUBICIN; FEMALE; IMMUNIZATION; MICE; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS;

EID: 70350572330     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.09.008     Document Type: Article

References (33)

1. DeVita V.T. Principles of cancer management: chemotherapy. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer principles and practice of oncology (1997), Lippincott-Raven, Philadelphia, PA 333-348
2. Barry M.A., Behnke C.A., and Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxin and hyperthermia. Biochem Pharmacol 40 (1990) 2353-2362
3. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood 89 (1997) 1845-1853
4. Wijermans P.W., Gerrits W.B., and Haak H.L. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50 (1993) 292-296
5. Glaser M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J Exp Med 149 (1979) 774-779
6. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170 (2003) 4905-4913
7. Proietti E., Greco G., Garrone B., Baccarini S., Mauri C., Venditti M., et al. Importance of cyclophosphamide-induced bystander effect on T cells for successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101 (1998) 429-441
8. Mace K., Mayhew E., Mihich E., and Ehrke M.J. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res 48 (1988) 130-136
9. Eralp Y., Wang X., Maughan W., MF P., and Lachman L.B. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6 (2004) R275-R283
10. + T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther 15 (2008) 1176-1183
11. Lin K.-Y., Guarnieri F.G., Levitsky S.-O.K., HI A.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 (1996) 21-26
12. + T-cell immune responses and enhances vaccine potency. Mol Ther 15 (2007) 1211-1219
13. Ji H., Wang T.L., Chen C.H., Hung C.F., Pai S., Lin K.Y., et al. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum Gene Ther 10 (1999) 2727-2740
14. Wu T.C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H.I., Hedrick L., et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92 (1995) 11671-11675
15. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60 (2000) 1035-1042
16. + T cell. Hum Gene Ther 18 (2007) 1129-1139
17. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3 (2003) 253-257
18. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
19. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 184 (1996) 747-752
20. Mueller S.N., Jones C.M., Stock A.T., Suter M., Heath W.R., and Carbone F.R. CD4+ T cells can protect APC from CTL-mediated elimination. J Immunol. 176 (2006) 7379-7384
21. Wen T., Bukczynski J., and Watts T.H. 4-1BB ligand-mediated costimulation of human T cells induces CD4+ and CD8+ T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 168 (2002) 4897-4906
22. Björck P., Banchereau J., and Flores-Romo L. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. Int Immunol. 9 (1997) 365-372
23. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., and Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87 (2002) 21-27
24. Tsimberidou A.M., Younes A., Romaguera J., Hagemeister F.B., Rodriguez M.A., Feng L., et al. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 104 (2005) 345-353
25. Maccubbin D.L., Wing K.R., Mace K.F., Ho R.L., Ehrke M.J., and Mihich E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 52 (1992) 3572-3576
26. + T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther 15 (2008) 677-687
27. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61 (2001) 3689-3697
28. Nigam A., Yacavone R.F., Zahurak M.L., Johns C.M.S., Pardoll D.M., Piantadosi S., et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Cancer 12 (1998) 161-170
29. Jaiswal A.I., and Croft M.J. CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response. J Immunol 159 (1997) 2282-2291
30. Josien R., Li H.L., Ingulli E., Sarma S., Wong B.R., Vologodskaia M., et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191 (2000) 495-502
31. Ouaaz F., Arron J., Zheng Y., Choi Y., and Beg A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16 2 (2002) 257-270
32. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
33. Tong Y., Song W., and Crystal R.G. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61 (2001) 7530-7535